Last reviewed · How we verify

Ipratropium/albuterol — Competitive Intelligence Brief

Ipratropium/albuterol (Ipratropium/albuterol) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination bronchodilator (anticholinergic + beta-2 agonist). Area: Respiratory/Pulmonology.

marketed Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (ipratropium); beta-2 adrenergic receptor (albuterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Ipratropium/albuterol (Ipratropium/albuterol) — National Jewish Health. Ipratropium is an anticholinergic bronchodilator that blocks muscarinic receptors to relax airway smooth muscle, while albuterol is a beta-2 agonist that stimulates bronchodilation through a different pathway, providing complementary airway relaxation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ipratropium/albuterol TARGET Ipratropium/albuterol National Jewish Health marketed Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (ipratropium); beta-2 adrenergic receptor (albuterol)
Atrovent + Bricanyl or Atrovent + Ventoline Atrovent + Bricanyl or Atrovent + Ventoline University Hospital, Tours marketed Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor
Duovent HFA Duovent HFA Centre Hospitalier Universitaire UCLouvain Namur marketed Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptors
Ipratropium + Levosalbutamol Free Dose Combination Ipratropium + Levosalbutamol Free Dose Combination Neutec Ar-Ge San ve Tic A.Ş phase 3 Combination bronchodilator (anticholinergic + beta-2 agonist) Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination bronchodilator (anticholinergic + beta-2 agonist) class)

  1. Centre Hospitalier Universitaire UCLouvain Namur · 1 drug in this class
  2. National Jewish Health · 1 drug in this class
  3. Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class
  4. University Hospital, Tours · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ipratropium/albuterol — Competitive Intelligence Brief. https://druglandscape.com/ci/ipratropium-albuterol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing